
Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC
November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa
Updated on: October 17,2023
290

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC
November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa
Updated on:October 17,2023
290
